Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA
Supernus Pharmaceuticals, Inc. PDUFA Target Action Date of February 1, 2025 ROCKVILLE, Md., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical compa...